Anavex Life Sciences Corp (OTCMKTS:AVXL) is delighted as well as encouraged by the recent results of report published in the journal Neuroscience Letters. For the first time a report states that real-time in vivo “imaging microglial inflammation”, linked with destructive neurodegenerative diseases, can be eliminated by sigma-1 receptor activation. It can reduce the negative impact that arises due to chronic microglia over-activation. Whenever there is over-activation, the extensive cell death occurs resulting in neurodegenerative diseases like Alzheimer’s disease and brain injury.
What the report says?
Anavex explained that Microglia is nothing but the immune cells of the CNS. These immune cells get activated whenever there is a brain injury and move towards the damaged area. Their role is to clear the area by reducing dying neurons. However, when the reaction is analyzed in context of neurological problems, the responses of immune cells are inflated and even lead in neurodegeneration.
As per the report, the so-called sigma-1 receptor stops harmful chronic microglial actions. The response was seen to be specific to stop responses as the reaction allowed the normal microglia activities within the brain.
The promising results
Christopher U. Missling, the President of Anavex stated that the published report results are very promising. The findings seem to further verify the beneficial response of sigma-1 receptor agonists. It highlights the significance of ANAVEX 2-73. The drug is in a Phase II a clinical trial. When sigma-1 receptor activity is enhanced via agonists, there is reduced harmful impact of inflated microglial response and neuroinflammation in terms of numerous neurodegenerative diseases. The data point to an understandable function in modulating microglial responses.
On Friday’s trading session, the stock price of Anavex surged 4.76% to close the trading session at $0.330. The gains came at a share volume of 476,167 compared to average volume of 1.08 million.
